To enable knowledge-sharing around Cervical cancer screening including the benefits of early screening with extended genotyping, BD (Becton, Dickinson, and Company) recently organized the ‘Shape the future of Cervical Cancer screening‘ discussion forum for pathologists, obstetricians, and gynecologists in Varanasi and Delhi-NCR. The Program was organized in association with the Association of Obstetricians and Gynaecologists of Delhi (AOGD), the Indian Society of Colposcopy and Cervical Pathology (ISCCP), and The Association of Gynecologic Oncologists of India (AGOI), Forum of obstetricians and gynecologists of south Delhi (FOGSd).
Dr. Jeff Andrews, Vice president Medical & Scientific Affairs – BD at Cervical Cancer Screening Forum
The forum discussed the importance of HPV DNA testing with cytology triage in cervical cancer screening. The forum also discussed the need for at-home collection and its role in addressing the challenge of reaching women who are unable to visit a gynecologist for routine cervical cancer screening.
Commenting on the initiative, Atul Grover, Managing Director, BD India/South Asia said, “We are committed to Advancing the world of health and that encompasses leading the dialogue and providing platforms to create awareness around critical women health concerns such as cervical cancer screening solutions. Through our Shape the future of Cervical Cancer screening event, we are hopeful to have brought the spotlight on patient benefits of early screening with extended genotyping with the support and participation of more than 100 leading gynecologists and obstetricians, pathologists, and molecular biologists.”
Human Papilloma Virus infection is a leading cause of cervical cancer; each year, nearly 73,000 women in India die from the disease-about one-quarter of the global disease burden. The American Cancer Society (ACS) recommends that screening for cervical cancer should start at age 25 and, for women without a history of cervical pre-cancer or cancer, the preferred method for screening for cervical cancer is by primary HPV screening every five years.
Present on the occasion, Dr. Jeff Andrews, Vice President of Global Medical Affairs at BD shared, “It is well known that different high-risk HPV genotypes carry different risks of cervical pre-cancer, and without the specific knowledge of the HPV genotype women may be under-treated or over-treated. Extended genotyping reporting benefits primary HPV screening and reporting of results from self-collection for HPV screening.”
The BD Onclarity™ HPV Assay detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis and provides genotyping information from specimens collected for cervical cancer screening purposes. The BD Onclarity™ HPV Assay includes genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68, and 56/59/66.
Unfortunately, over half of all cervical cancers are diagnosed in women who have never been screened or have not been screened in the previous five years. This situation has been further compounded by the recent global pandemic.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.